TY - JOUR
T1 - Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells
AU - Ruiz-González, Rubén
AU - Milán, Paula
AU - Bresolí-Obach, Roger
AU - Stockert, Juan Carlos
AU - Villanueva, Angeles
AU - Cañete, Magdalena
AU - Nonell, Santi
N1 - Funding Information:
The research described herein has been supported by the Ministerio de Economía y Competitividad through the grants CTQ2013-48767-C3-1-R and CTQ2013-48767-C3-3-R (Spain) and by Obra Social “la Caixa” through Universitat Ramon Llull with a research grant for seed projects (ref. 2016-URL-Trac-013). Roger Bresolí-Obach thanks the European Social Funds and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya for his predoctoral fellowship (2016 FI_B1 00021).
Publisher Copyright:
© 2017 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2017/2/17
Y1 - 2017/2/17
N2 - A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
AB - A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
KW - Doxorubicin
KW - HeLa cells
KW - Pheophorbide a
KW - Photodynamic therapy
KW - Synergic treatment
UR - http://www.scopus.com/inward/record.url?scp=85013987570&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000398722500008&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.3390/cancers9020018
DO - 10.3390/cancers9020018
M3 - Article
C2 - 28218672
AN - SCOPUS:85013987570
SN - 2072-6694
VL - 9
JO - Cancers
JF - Cancers
IS - 2
M1 - 18
ER -